Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04972097 · ClinicalTrials.gov registry record · NA
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
A NA study, sponsored by Angiodynamics.
- Completed
- Registry status
- NA
- Development phase
- 121
- Enrollment target
NCT04972097 is a NA study that has completed, run by Angiodynamics. The registered enrollment target is 121 participants.
The verdict
NCT04972097, a NA study, has completed, sponsored by Angiodynamics.
- COMPLETED
- Registry status
- NA
- Development phase
- 121 participants
- Enrollment target
Study Summary
Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
Interventions
- DEVICE Irreversible Electroporation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2024-08-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04972097
The ClinicalTrials.gov registry entry for NCT04972097 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Angiodynamics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irreversible Electroporation is the first listed.
NCT04972097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04972097 about?
NCT04972097 is a clinical study titled "Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue". Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
What is the current status of trial NCT04972097?
This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2022-03-29. Estimated completion is 2024-08-14.
What interventions are being tested in trial NCT04972097?
The interventions under investigation include: Irreversible Electroporation (DEVICE).
Who is sponsoring clinical trial NCT04972097?
This trial is sponsored by Angiodynamics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.